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ABSTRACT
The heterogeneous collection of nucleosome
remodelling and deacetylation (NuRD) complexes
can be grouped into the MBD2- or MBD3-containing
complexes MBD2–NuRD and MBD3–NuRD. MBD2 is
known to bind to methylated CpG sequences in vitro
in contrast to MBD3. Although functional differ-
ences have been described, a direct comparison of
MBD2 and MBD3 in respect to genome-wide binding
and function has been lacking. Here, we show that
MBD2–NuRD, in contrast to MBD3–NuRD, converts
open chromatin with euchromatic histone modifica-
tions into tightly compacted chromatin with
repressive histone marks. Genome-wide, a strong
enrichment for MBD2 at methylated CpG sequences
is found, whereas CpGs bound by MBD3 are devoid
of methylation. MBD2-bound genes are generally
lower expressed as compared with MBD3-bound
genes. When depleting cells for MBD2, the MBD2-
bound genes increase their activity, whereas MBD2
plus MBD3-bound genes reduce their activity. Most
strikingly, MBD3 is enriched at active promoters,
whereas MBD2 is bound at methylated promoters
and enriched at exon sequences of active genes.
INTRODUCTION
The nucleosome remodelling and deacetylation (NuRD)
complex harbours a multi-functional and highly conserved
combination of chromatin-modifying activities. Through
the MBD2 and MBD3 proteins, with their methyl-
CpG-binding domains (MBD), the NuRD complex
combines reading of DNA methylation marks with mod-
ifying histones [for recent reviews see (1,2)]. Through the
combinatorial assembly of similar, paralogous versions of
histone deacetylases, nucleosome-remodelling ATPases,
metastasis-associated (MTA) factors and others, biolo-
gical speciﬁcity of the NuRD complex is achieved during
development, oncogenesis and cancer progression.
Speciﬁcity mediated by or associated with MBD2 and
MBD3 has been documented on several levels. MBD2-
knockout mice are viable and fertile with subtle defects
only, whereas MBD3-knockout mice are embryonic
lethal (3). On the molecular level, both proteins differ in
respect to binding to methylated DNA. MBD2 is able to
bind DNA with a 5-methylcytosine (5mC) modiﬁcation
(4,5), in contrast to MBD3, which binds to 5-hydrox-
ymethylcytosine (5 hmC), but not to 5mC (4–7).
Puriﬁcation and analysis of NuRD complexes revealed
that MBD2 and MBD3 are components of mutually ex-
clusive NuRD complexes, MBD2–NuRD and MBD3–
NuRD (8). Despite these and other differences, both
factors have been shown to interact with GATAD2A/
p66a and GATAD2B/p66b within the NuRD complex
(9–11), as well as with CSB (Cockayne Syndrome
Protein B) (12), HIC1 (Hypermethylated in Cancer 1)
(13) and DOC-1 (Deleted in Oral Cancer 1) (14).
Testing of Hela cell promoter regions revealed preferen-
tial MBD2 binding near transcriptional start sites (TSS)
(15). Genome-wide binding analysis of NuRD complexes
in ES cells, which are primarily MBD3–NuRD complexes,
revealed a broad binding near promoters, but with a gap at
the TSS (16). In contrast, ChIPseq analysis of MBD3 in ES
cells revealed a sharp occupancy at the TSS (7). In addition
to these published differences for MBD3–NuRD binding
distribution, a direct comparison between MBD2 and
MBD3 on the whole genome level is missing.
Because of the increasing information for both func-
tional differences as well as similarities, we wanted
to know whether MBD2 and MBD3 differ in respect to
chromatin modiﬁcation and in genome-wide binding.
Functional tests revealed a dramatic difference in that
MBD2–NuRD, but not MBD3–NuRD, transformed
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euchromatin into repressed chromatin. Analysis of the
genome-wide binding pattern of MBD2 and MBD3
within the same cell type showed a preference for MBD2
to be bound at methylated CpG islands and inactive pro-
moters, whereas MBD3 was found at unmethylated CpG
islands and active promoters. Most strikingly, exon se-
quences of active genes were enriched for MBD2 binding.
MATERIALS AND METHODS
Antibodies
Immunostaining was done using commercial antibodies
recognizing Mi2 (Santa Cruz, sc-11378), RbAp46 (Santa
Cruz, sc-8272), HDAC1 (Santa Cruz, sc-9397), MBD2
(Santa Cruz, sc-9397) and MBD3 (Santa Cruz, sc-9402).
For ChIP H3K9ac (Abcam, 4441), H3K9me3 (Abcam,
8898), GFP (polyclonal rabbit antiserum was raised
against full length GFP), MBD2a/b (Sigma Aldrich,
M-7318), MBD3 (Bethyl Laboratories A302-528A),
normal rabbit control IgG (Abcam, ab46540) antibodies
and in addition V5-agarose (Sigma Aldrich, A7345) was
used. GFP, MBD2a/b and MBD3 antibodies were used
for Western Blot as well.
Luciferase assay
A10 cells were co-transfected with 1 mg of either GFP-
LacI, GFP-LacI-VP16, GFP-LacI-MBD2a, GFP-LacI-
MBD2b or GFP-LacI-MBD3 and bGAL-vector using
TurboFect (Fermentas) in six-well plates. Cells were har-
vested 48 h after transfection and lysed with 300 ml lysis-
buffer (25mM Tris/HCl pH 7.5, 8mM MgCl, 1mM
EDTA, 1% Triton X 100, 15% glycerin and freshly
added 1mM DTT) per well. Luciferase reporter activity
was determined and corrected for bGAL expression.
Data deposition
The microarray and the ChIPseq data from this publica-
tion have been submitted to the GEO database as entry
GSE41010.
Cell lines and transfection, Immunoﬂuorescence analysis,
Western Blot, Chromatin immunoprecipitation and
ChIPseq analysis and bioinformatics analyses
See Supplementary online material.
RESULTS
The NuRD complex can be assembled on LacO repeats
To study possible MBD2- or MBD3-induced changes in
chromatin compaction, we used the LacO/LacI system
that uses 100s of LacO repeats integrated into single
genomic loci (17). In many cases, genomic integration of
the repeat cluster is found in heterochromatic regions. For
such a situation, we used the F42B8 cell clone of U2OS
cells, with a repeat cluster integrated close to the centro-
mere (18). As a model for a euchromatic array, we used
the RREB1 cell clone of CHO cells (19). In a ﬁrst set of
experiments, we wanted to know whether an MBD2 or
MBD3 fusion with the DNA-binding domain of the Lac
repressor LacI can be targeted to a LacO array, and
whether such a bound protein recruits additional compo-
nents of the NuRD complex. For this, we started with the
heterochromatic array of the F42B8 cells, as the compact
structure of such an array can be easily visualized and
analysed by cytological methods. As a requirement for
these experiments, we analysed the heterochromatic
nature of the array to assure that it is lacking NuRD com-
ponents. The array can be easily identiﬁed by expression
of a GFP-LacI fusion (Supplementary Figure S1) and was
found to be devoid of NuRD components. In contrast to
the expression of GFP-LacI, both MBD fusions,
GFP-LacI-MBD2b and GFP-LacI-MBD3, resulted in
positive staining by immunoﬂuorescence with antibodies
against the NuRD components Mi2, HDAC1 and
RbAp46 (Figure 1A). Thus, these NuRD factors were
recruited by MBD2 or MBD3 targeted to the LacO array.
For MBD2, two isoforms are known, MBD2b and
MBD2a, that contains an N-terminal extension.
Within the assays described in this manuscript, there was
no difference seen between using GFP-LacI-MBD2a or
GFP-LacI-MBD2b (Supplementary Figure S2).
Recruitment of GATAD2B was detected by co-expressing
Cherry-GATAD2B (Figure 1A). When using GATAD2B
fused to GFP-LacI (GFP-LacI-GATAD2B), the NuRD
components Mi2, HDAC1 and RbAp46 could be similarly
recruited to the LacO array (Supplementary Figure S3).
Furthermore, GFP-LacI-GATAD2B also recruited
MBD2 and MBD3 to the array. This might potentially be
a source for generating mixed complexes, i.e. MBD2
recruits GATAD2B, which in turn might recruit MBD3.
To test for this potential problem, we co-expressed
GFP-LacI-MBD2 with Cherry-MBD3 or GFP-LacI-
MBD3 with Cherry-MBD2. These combinations clearly
showed that binding of neither of the MBD factors
resulted in recruitment of the paralogous factor to the
array and that only homogeneous NuRD complexes were
generated on the array (Supplementary Figure S4). In
addition, we targeted HDAC1 to the LacO array by the
use of GFP-LacI-HDAC1, but this did not result in
assembly of the NuRD complex (Supplementary Figure
S5). The results of these experiments are summarized in
Figure 1B and demonstrate that the LacO array system is
suitable to study NuRD. Furthermore, MBD2, MBD3 or
GATAD2B can be used as starting component to assemble
the NuRD complex. When targeting MBD2 to the DNA,
only MBD2–NuRD is assembled, as is the case for MBD3,
which assembles solely MBD3–NuRD.
In contrast to MBD3, MBD2 converts euchromatin into
repressed chromatin
To study the repressive function of NuRD, we used the
above LacO/LacI targeting system within a euchromatin
background. This was provided by the RREB1 cell clone
(19). NuRD complex assembly was similarly possible as
with the heterochromatin array of the F42B8 cells above
(Supplementary Figure S6). After transfection of GFP-
LacI, the expanded array can be visualized. Upon expres-
sion of GFP-LacI-MBD2, the expanded array
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dramatically shrinks to a small spot similarly as seen for
the heterochromatin array of the F42B8 cells. This array
compression is observed when targeting MBD2a or
MBD2b to the LacO array (Figure 2), but is not seen
when GFP-LacI-MBD3 is expressed. Similarly, the array
remains expanded when expressing GFP-LacI-HDAC1, a
factor that is not able to assemble the NuRD complex on
the LacO array (Figure 1B). If array binding, and there-
fore compaction, was indeed caused by the DNA-bound
MBD2–NuRD complex, recruitment should be dependent
on the LacI DNA-binding domain. Indeed, the deleted
DNA-binding domain in construct GFP-LacI-MBD2b
resulted in a nuclear GFP staining not localized to the
LacO array (Supplementary Figure S7). We wanted to
test whether the compaction of the chromatin array is
marked by the chromatin modiﬁcation H3K9me3, which
is speciﬁc for inactive and repressed chromatin. Therefore,
we puriﬁed chromatin for immune-precipitation with
antibodies speciﬁc for H3K9me3 or H3K9ac. The ratio
of these precipitations is a mark for active or for repressed
chromatin. In contrast to cells transfected with GFP-LacI,
expression of GFP-LacI-MBD2a resulted in a strong
increase of the repressive mark and a similarly strong
decrease of the active mark. In contrast, expression of
GFP-LacI-MBD3 induced a lower decrease in H3K9ac
and a lower increase in H3K9me3 (Supplementary
Figure S8). This low, but reproducible, effect of MBD3
in the absence of chromatin compaction may indicate that
these modiﬁcation changes are not sufﬁcient to compact
chromatin as is the case with MBD2.
To study the relationship between the chromatin status
and gene activity, we generated HeLa cell clones contain-
ing an integrated luciferase reporter gene. The luciferase
gene is controlled by seven copies of the LacO sequence,
such that any LacI fusion protein (Figure 3A) can be
tested for its regulatory capacity. We selected a single
clone (A10), from several different cell clones based on
the robust ground state of luciferase activity, which was
expected to be further increased by an activator or to be
reduced by a repressor. Indeed, transient control transfec-
tion with an expression plasmid coding for a GFP-LacI-
VP16 fusion resulted in a 8-fold increase of luciferase
activity (Figure 3C). Expression of GFP-LacI-MBD2a,
GFP-LacI-MBD2b or GFP-LacI-MBD3 in clone A10
led to comparable amounts of the respective fusion
protein (Figure 3B). Preparing these cells for ChIP
analysis with an antibody directed against GFP allowed
for the detection of the GFP-LacI-MBD fusions bound at
the LacO repeats (Figure 3D). Luciferase gene activity was
determined without transfection or after expression of
GFP-LacI or of the MBD fusion factors (Figure 3C).
Expression of either MBD2a or MBD2b led to a
10-fold reduction of luciferase activity, in contrast to
the GFP-LacI control or to GFP-LacI-MBD3.
Clearly, MBD2 mediates strong chromatin compaction
and transcriptional repression, whereas MBD3 does not.
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Figure 1. LacI-MBD2 or LacI-MBD3 assemble MBD2–NuRD or
MBD3–NuRD on the LacO array. (A) F42B8 (U2OS) cells were trans-
fected with GFP-LacI-MBD2b or GFP-LacI-MBD3. GFP or Cherry
signals were directly determined, and indirect immunoﬂuorescence was
carried out with antibodies against Mi2 (aMi-2), RbAp46 (aRbAp46)
and HDAC1 (aHDAC1). Merged colour images show DAPI staining
in addition. (B) Schematic representation and summary of the assembly
of the different NuRD components. Green arrows indicate recruitment
of the components pointed out by the arrowhead, whereas the grey
arrows indicate no assembly.
GFP-LacI GFP-LacI-MBD2a GFP-LacI-MBD2b
GFP-LacI-MBD3 GFP-LacI-MBD3 GFP-LacI-HDAC1
Figure 2. In contrast to MBD3 and to other NuRD components,
LacI-MBD2a or LacI-MBD2b dramatically compact the euchromatic
LacO array. RREB1 cells were transfected with GFP-LacI,
GFP-LacI-MBD2a/b, GFP-LacI-MBD3 and GFP-LacI-HDAC1 as
indicated. Samples were visualized for DNA (blue) and GFP (green).
The arrows point to the compact array or to the expanded array
(dotted circle).
3012 Nucleic Acids Research, 2013, Vol. 41, No. 5
 at Bibliothekssystem
 der U
niversitaet G
iessen on A
ugust 20, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Therefore, we determined the chromatin modiﬁcation at
the reporter gene with antibodies against H3K9me and
against H3K9ac. The ratio of methylated K9 versus
acetylated K9 is an indication for repressed chromatin.
GFP-LacI-MBD2a and GFP-LacI-MBD2b expression
resulted in an increased repression ratio in contrast to
GFP-LacI-MBD3, which did not change the repression
ratio as compared with the GFP-LacI control expression
(Figure 3E and F).
Both MBD2 or MBD3 bind to similar sequence classes
Because of the functional differences ofMBD2 andMBD3,
we wanted to know whether both factors are targeted to
factor-speciﬁc sites throughout the genome. Such an
analysis has not yet been performed within a single cell
type. The quality and speciﬁcity of available antibodies
directed against these two proteins is a limiting factor in
carrying out chromatin precipitation experiments.
Therefore, we generated MBD versions fused to the V5
domain. This domain has been shown to be a universal
and optimal tag for ChIPchip or ChIPseq analysis (20).
Expression of V5, V5-MBD2b or V5-MBD3 in HeLa
cells did not alter cell proliferation. Western-blot
detection of the tagged MBD factors revealed similar
amounts of proteins expressed from the different con-
structs (Supplementary Figure S9A). Therefore, we
generated chromatin from HeLa cells after expression of
these three constructs and puriﬁed V5 bound DNA for
ChIPseq. We identiﬁed regions of signiﬁcant binding for
MBD2 and MBD3 by comparing precipitations from cells
transfected with V5-MBD2 and V5-MBD3 with those
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Figure 3. In contrast to GFP-LacI-MBD3, GFP-LacI-MBD2a or GFP-LacI-MBD2b repress the euchromatic LacO promoter. (A) Illustration of the
reporter-gene including seven LacI-binding sites (LacO-repeats). Reporter construct was used to generate stable reporter cell clones in HeLa cells. (B)
Western Blot analysis of the indicated GFP-LacI-fusion proteins expressed in the stable A10 clone. GAPDH antibody was used as loading control.
(C) The A10 clone was transiently transfected with either GFP-LacI, GFP-LacI-VP16, GFP-LacI-MBD2a, GFP-LacI-MBD2b or GFP-LacI-MBD3.
Gene activity is expressed as fold change relative to the untransfected A10 clone. (D) Binding analysis by ChIP-qPCR was performed after trans-
fection of the indicated constructs using a GFP antibody and expressed relative to untransfected cells. (E, F) GFP-LacI-MBD2a and
GFP-LacI-MBD2b change the H3K9me3/H3K9ac ratio after binding to the reporter. ChIP-qPCR was performed with antibodies recognizing
H3K9ac (E) and H3K9me3 (F) and expressed relative to input. Error bars indicate the standard error of three individual replicates.
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from cells transfected with the vector expressing the V5
tag only. We used PeakRanger to call peaks with a
P-value <10–5 at an FDR <5%. Using this approach,
we were able to detect 8200 MBD2- and 490 MBD3-
binding regions. Despite this difference in the number of
binding sites, both factors were found to bind to similar
sequence classes. The peak distribution indicates highly
speciﬁc binding to transcriptional start sites including
upstream sequences (Figure 4A and B). Furthermore,
exon sequences are highly enriched including transcrip-
tional end sites. In contrast, intron sequences are under-
represented as compared with the total genomic sequence
distribution (Figure 4A and B). In contrast to sequences
associated with genes, intergenic sequences are almost
depleted from either MBD2 or MBD3 binding
(Figure 4B).
Binding speciﬁcity was veriﬁed at positive and negative
sites (Supplementary Figure S9B). To conﬁrm that
MBD2- or MBD3-binding sites are represented by the
V5-tagged MBD proteins, we used the host HeLa cells
without transfection and immune-precipitated chromatin
with antibodies directed against MBD2 or MBD3.
Although the speciﬁcity and efﬁciency of these antibodies
was low, we could conﬁrm MBD2 and MBD3 binding
even without expression of the tagged protein (Sup-
plementary Figure S10).
Binding to the transcriptional start sites was highly
position speciﬁc with a sharp peak at the TSS
(Figure 4C). Because of the lower number of MBD3-
bound sites, the binding peak at the TSS was less
pronounced. No speciﬁc enrichment of promoter DNA
could be detected in the ChIPseq data from cells transfected
with the empty V5 vector.
Because similar sequence classes are bound by
both MBD factors, we tested for a possible overlap of
binding sites. We determined the cumulative binding
proﬁles for MBD2 and MBD3 across MBD2 and MBD3
peak regions. As expected MBD2 and MBD3 binding can
be detected across the respective peak regions (Figure 4D).
Interestingly, we are able to detect strong MBD2 binding
even across MBD3 peak regions (Figure 4D, central panel;
for genome-browser examples see Supplementary Figure
S11), although the analysis of overlapping peaks suggested
only moderate overlap between MBD2 and MBD3 peak
ranges (Figure 5A). In contrast, we cannot detect much
MBD3 binding across MBD2 peak regions (Figure 4D,
right panel).
Thus, overall binding of MBD2 or MBD3 is targeted to
similar sequence classes and MBD3 sites are often marked
by robust MBD2 binding.
MBD2 sites are highly enriched for methylated DNA,
whereas MBD3 sites are devoid of methylation
Despite the similarity of the MBD domains of MBD2 and
MBD3, it has been shown that only MBD2 is able to bind
to methylated CpG islands in vitro (4). The genome-wide
methylation pattern of HeLa cells is known [GSE40699
(22)]. CpG dinucleotides are underrepresented in the
genome and occur in two classes, dispersed throughout
the genome and clustered within CpG islands (23). Both
MBD2- and MBD3-binding sites are highly enriched for
CpG islands (Figure 5A). Seventy-nine per cent of the
MBD2 peaks are overlapping with CpG islands and in
case of MBD3, 69% are overlapping. The MBD2
overlap with CpG islands involves a sub-fraction (22%)
of the CpG islands only. Taking into account that a
sub-fraction of CpG islands in HeLa cells is methylated,
we determined binding of both MBD factors to
methylated CpG islands. For MBD2, a high percentage
of the MBD2-bound CpG islands were methylated,
whereas for MBD3, <10% of the bound CpG islands
were methylated (Figure 5B).
Thus, although both factors bind to similar sequence
elements such as TSS and CpG islands, their binding
differs dramatically in respect to CpG methylation.
MBD2 is associated with repressed genes and MBD3
with activated genes
Because we have seen the striking difference between
MBD2 and MBD3 in mediating reporter-gene repression
and chromatin compaction, we compared MBD2 and
MBD3 promoter binding in respect to gene activity.
Indeed, MBD2 is bound to promoters of genes with low
transcriptional activity, whereas MBD3-bound promoters
show a 4-fold higher gene activity, as determined from the
mean values (Figure 6A). When comparing these differ-
ences with the activity of all genes in HeLa cells, MBD2
was found to be associated with genes with lower tran-
scriptional activity as compared with all genes. In
contrast, gene activity of MBD3-associated genes was
higher than the mean activity of all genes (Figure 6A).
To gain insights into the MBD2 or MBD3 function in
the context of the endogenous gene repertoire, we depleted
HeLa cells by RNAi against either MBD protein or as a
negative control with control siRNA, determined the re-
spective expression proﬁles on the Affymetrix GeneChip
Gene 1.0 ST Array platform and veriﬁed expression
changes at individual genes (Supplementary Figures S12
and S13). In almost all cases, when well-studied repressors
have been depleted, the expression proﬁles of target genes
not only increased, but also a substantial number of genes
decreased their expression. Similarly, depletion of
well-characterized activators resulted in decreased as well
as in increased gene activity (e.g. data compiled at http://
www.ncbi.nlm.nih.gov/geo/). One of several reasons for
this is an indirect effect on genes that do not harbour a
binding site for the respective factor. Therefore, we
focussed our view on 1080 genes with MBD2 binding
within the promoter region (Figure 6B). The majority of
these genes show a mild change in gene activity towards
activation. In comparing MBD2 depletion with MBD3
depletion of MBD2-bound genes, an increase in gene
activity of >75% is seen after MBD2 RNAi (red curve
in Figure 6C shifted to the right). Because the expression
changes are rather low, we wanted to determine the sig-
niﬁcance of this observation. Therefore, we determined
the expression change of all genes, irrespective of a
MBD2-binding site (Figure 6C) and found that 50% of
these are either induced or repressed. This difference
between MBD2-bound genes and all genes was signiﬁcant,
3014 Nucleic Acids Research, 2013, Vol. 41, No. 5
 at Bibliothekssystem
 der U
niversitaet G
iessen on A
ugust 20, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
with a P value of 7 10–76. Expression changes after
MBD3 depletion of MBD2-bound genes resulted in
equal gene numbers repressed or induced. Similarly, we
analysed genes with MBD2 binding to exon sequences
(see below) and found that these genes responded with a
slight shift towards activation upon MBD2 depletion
(Figure 6C green line). Similar results were achieved,
when we used the gene set enrichment analysis (GSEA;
Supplementary Figure S14). Thus, again MBD2 functions
primarily as a repressor at MBD2-bound genes.
Because MBD3 is found at non-methylated DNA (see
above), we wanted to test for a possible functional differ-
ence of both MBD factors by analysing gene expression
changes of 271 MBD3-bound genes upon MBD3 deple-
tion. Small changes were found, resulting in both slightly
increased or decreased activity of genes (Figure 6D). The
binding analysis of MBD3-bound promoters shows a sig-
niﬁcant number of cases with MBD2 binding as well
(heatmap in Figure 6D). In contrast to the whole
genome binding analysis, where we applied a stringent
peak-calling algorithm (compare Figure 5A), here within
this small set of sites, we applied a different peak-calling
algorithm (Macs) with less stringent settings. This revealed
140 of MBD3-bound promoters to be signiﬁcantly
associated with MBD2 peaks as well. Therefore, we
asked for the effect of MBD2 depletion on the activity
of these genes. For these, we found expression changes
towards repression (red curve in Figure 6E shifted to the
left). The difference in expression change after MBD2 de-
pletion at MBD2 plus MBD3-bound genes and expression
change of all genes after MBD3 depletion (black curve in
Figure 6E) is signiﬁcant (P< 6 105).
Therefore, we can conclude that MBD2 primarily
causes gene repression, whereas MBD2 in the context of
MBD3 promoter binding might be involved in gene
activation.
In contrast to MBD2, MBD3 is associated with chromatin
modiﬁcation characteristic for active chromatin
To identify additional chromatin features MBD2 and
MBD3 might be associated with, we compared the
binding sites with known features of histone modiﬁcation
in HeLa cells. First, we identiﬁed that MBD3-bound sites
are generally associated with open chromatin as indicated
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and MBD3 bind to TSS. Plotted is the average proﬁle of V5-MBD2, V5-MBD3 or V5 read coverage in a 6000 bp window around the TSS of all
RefSeq genes. (D) MBD3 sites are often co-occupied by MBD2. Plots illustrate average V5 binding (left panel), V5-MBD2 (center panel) and
V5-MBD3 binding (right panel) over MBD2 peaks (orange) and MBD3 peaks (blue).
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by the precise peaks in the FAIRE (Formaldehyde-
Assisted Isolation of Regulatory Elements) (24) and
DNaseI proﬁles. In contrast, MBD2 sites are not in an
open conformation.
Additionally, we found for MBD3 a correlation with
active promoter marks H3K4me2, H3K4me3 and
H3K9ac at MBD3-binding sites, which is in line with
MBD3 binding to promoters of actively transcribed
genes (Figure 6A) and to non-methylated CpG islands
(Figure 5B), which often are found at active promoters.
Indeed, MBD3 binding clearly correlated with these active
promoter marks (Figure 7) with the characteristic ‘dip’ of
the respective marks, since transcriptional start sites and
other regulatory sites are depleted from nucleosomes. In
general, sites occupied by both MBD factors (grey line in
Figure 7) show similar features as the MBD3 sites. This
binding is in stark contrast to MBD2, which does not
show any correlation with these marks. A similar differ-
ence for the two MBD factors is seen with polymerase II
binding at MBD3 sites, but not at MBD2-bound regions.
Contrary, testing speciﬁcally for marks associated with
silent chromatin, such as H3K9me3, we do not ﬁnd a
speciﬁc enrichment at MBD2 sites.
Because we have seen for both, MBD2 and MBD3, an
enrichment over gene and exon sequences (Figure 4A
and B), we wanted to compare the binding proﬁles with
chromatin marks characteristic for the gene body and for
transcriptional elongation, such as H3K36me3 and
H3K79me2 (25–27). These showed a preference for
MBD3 binding, but with a wide gap at the MBD3-
binding site (Figure 7). This pattern is best explained by
MBD3 binding to promoters, whereas the H3K36me3 and
the H3K79me2 signals are known to mark the gene body
with H3K79me2 peaking within the ﬁrst kb of the
transcribed region (28). Because these plots are compiling
genes in both orientations, the increase for these two
marks is seen on both sides of the MBD3-binding site.
We can conclude that chromatin modiﬁcations
associated with MBD2 or MBD3 binding is in line with
the LacO array studies, with reporter gene activity and
with the response of endogenous gene activity upon deple-
tion of either MBD factor.
MBD2 marks speciﬁcally exon sequences
Overall sequence class enrichment for MBD2 or MBD3
binding revealed that, among others, exon sequences were
targeted (see Figure 4A and B). Therefore, we compiled
the MBD2- and MBD3-binding sites at gene regions to
test for enriched exon sequences in comparison with
intron sequences. An instructive method is to plot
binding sites over a meta-gene. Therefore we plotted the
average MBD2/3 occupancy across 50-upstream, ﬁrst,
internal and last exons as well as 30-downstream regions
according to their position relative to all RefSeq tran-
scripts. (Figure 8A). With this analysis, a clear correlation
for MBD2 with exon sequences was evident, whereas
MBD3 was primarily detected at the promoter region
and overlapping into the ﬁrst exon. Control ChIPseq
using the V5 tag resulted in only a marginal preference
for the promoter region. The last exon, which is often
not translated to a varying extend, depicts a decline of
MBD2 binding from the 50end towards the transcriptional
end site. Such a ﬁnding is in line with results on DNA
methylation that promoter regions of inactive genes may
be methylated, whereas methylation of active genes is
found in gene bodies (29,30). To verify the MBD2-
binding pattern over the meta gene and to test for a de-
pendency on transcriptional activity, we grouped the
MBD2-binding sites into those binding to genes with
low or with high transcriptional activity. Again, the pref-
erence for exons is evident with a stronger enrichment at
the promoter and ﬁrst exon at genes with low or no tran-
scriptional activity, whereas the active genes show reduced
binding to the promoter and ﬁrst exon, but increased
binding to internal exons (Figure 8B).
Thus, we can conclude that MBD2 shows an exon spe-
ciﬁcity within active genes.
DISCUSSION
MBD2 and MBD3 have been analysed extensively for
possible functional differences and similarities. Striking
differences are embryonic lethality for MBD3-knockout
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mice (3) and differential expression of MBD3, but not
MBD2, found in ES cells (16). Similarity between these
two factors is given by their amino acid similarity
(sequence is 70% identical), and indeed, earlier work sug-
gested that both MBD factors are components of the same
complex such that MBD2 recruits MBD3 complexes to
methylated DNA (3). In contrast, complex puriﬁcation
revealed that both MBD proteins are incorporated into
similar, but separable, complexes MBD2–NuRD and
MBD3–NuRD (8). Furthermore, except for ES cells,
many cell types seem to express both factors (http://gen-
ome.csdb.cn/cgi-bin/hgTrackUi?hgsid=1142799&c=chr
X&g=gnfAtlas2). Despite the importance of both MBD
factors to read and to modify epigenetic marks, a direct
comparison of functional mechanisms and of target sites
has been missing.
In general, the NuRD complex with its histone
deacetylase activity is known as a factor that mediates
gene repression [for recent reviews see (2,31,32)].
Nevertheless, when comparing MBD2 with MBD3 in
their activities to effect reporter gene activity and chroma-
tin modiﬁcation, we could show that only MBD2 mediates
repression and chromatin compaction. This is in line with
the identiﬁcation of a trans-repression domain within
MBD2 (33).
The MBD has been deﬁned by its ability to bind
methylated CpG sequences. This was found for MBD2
in contrast to MBD3 (4,5). Because heterochromatic com-
paction of chromatin and DNA methylation correlate
(34,35), the most direct explanation of such a correlation
would be that the ‘reader’ of CpG methylation induces
chromatin compaction. Binding of MBD2 to methylated
DNA has been well established by in vitro experiments
(4,5). In vivo, sequence-speciﬁc targeting of MBD2 to
methylated CpGs has been tested (15). The authors
focussed on 25 000 promoters in HeLa cells and found
that MBD2 localized to the fraction of promoters
characterized by DNA methylation. Here, we extended
this analysis by testing the whole HeLa genome for
MBD2 binding. In fact, we ﬁnd MBD2 binding to be
highly correlated with methylated CpG sequences, irre-
spective of their location within the gene body or within
methylated promoter regions. Thus, MBD2 seems to be
the ‘reader’ for many of the methylated CpGs. Therefore,
it is interesting to note that MBD2 is also able to dramat-
ically compact a widely expanded euchromatic LacO array
such that MBD2 may also be the mediator of chromatin
compaction at methylated DNA sequences.
In addition to methylated DNA binding and chromatin
compaction, a functional effect on gene activity is
observed. Previous studies (36) are in agreement with
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Figure 6. MBD2 binding to promoters is associated with gene
repression and combined MBD2/MBD3 binding with gene activation.
(A) MBD3-bound genes are signiﬁcantly higher expressed than MBD2-
bound genes. Gene expression in HeLa cells as measured by Affymetrix
Gene 1.0 ST arrays [Wilcoxon signed rank test: P=2 1028 (MBD2)
and P=8 1033(MBD3)]. (B) Analysis of the expression level of 1080
MBD2-bound genes sorted by fold change after MBD2 knock down
(kd) in HeLa cells (left panel). Density map of ChIPseq data of MBD2
at these promoters shows MBD2 binding around the TSS (right panel).
(C) MBD2 represses transcription on MBD2 targets: Cumulative
density plot of gene expression changes after MBD2 kd (red) or
MBD3 kd (grey) on MBD2-bound promoters, and after MBD2 kd
on MBD2-bound exons (green) in HeLa cells in comparison with the
expression of all genes after MBD2 kd (black) (Wilcoxon signed rank
test: P=7 1076). (D) MBD3-knockdown results in gene repression.
Analysis of the expression level of 271 MBD3-bound genes sorted by
fold change after MBD3 kd in HeLa cells (left panel). Density map of
ChIPseq data from MBD3-bound promoters shows MBD3 binding
around the TSS (middle panel) as well as binding of MBD2 (right
Figure 6. Continued
panel). (E) Co-localization of MBD2 and MBD3 at TSS mediates gene
activation: Cumulative density plot depicts gene expression changes
after MBD2 kd (red) or MBD3 kd (grey) on MBD3-bound promoters
in HeLa cells in relation to the expression changes after MBD3
knockdown on all genes (black) (Wilcoxon signed rank test:
P=6 105).
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our observation that depletion of MBD2 results in
changes of gene expression characterized by a release
from repression. A more direct repressive role by MBD2
is evident from our binding site analysis that shows a
preference for MBD2 to be associated with genes of low
activity as compared with the mean activity of all genes.
Therefore, we focussed on these genes bound by MBD2
and could ﬁnd gene activation upon MBD2 depletion,
supporting the repressive role of MBD2 bound to
methylated CpGs.
For MBD3, a repressive function has been postulated
and has also been documented in a few cases. For
example, PML-RARa binds and recruits MBD3–NuRD
to target genes, thereby facilitating Polycomb binding and
H3K27 methylation (37). Recently, deacetylation of
H3K27 by MBD3 could be shown, which subsequently
causes H3K27 trimethylation (16). Nevertheless, when
depleting mouse ES cells from MBD3, a majority of
responsive genes are down-regulated (16), indicating that
a potential activation function is associated with MBD3.
This is in line with our HeLa cell analysis showing that
genome-wide binding of MBD3 is associated with genes
showing a signiﬁcantly higher expression as compared
with the mean value of the expression of all genes. This
non-repressive activity of MBD3 is further supported by
our ﬁnding that MBD3 neither causes chromatin
compaction nor does it repress reporter gene activity. In
general, we ﬁnd MBD3 binding to non-methylated CpGs,
i.e. active promoters, which often show MBD2 binding as
well. This is the small fraction of MBD2 sites that are not
methylated. In these cases, depletion of MBD3 activates as
well represses gene activity, whereas depletion of MBD2
causes a small down-regulation of the associated genes. A
dual role of a repressor complex in gene repression as well
as in gene activation is often triggered by the neighbouring
chromatin features. In case of MBD3, repression may
require synergizing repressive factors, which may be
absent in TSS regions bound by MBD3.
Overall, both MBD factors bind similar sequence
classes, which might support earlier results on MBD2 re-
cruiting MBD3 complexes (3), but the differences arguing
for separate complexes are prevailing. First, there is an
enrichment of promoter sequences, with MBD2 binding
to methylated and MBD3 binding to unmethylated pro-
moters. Previously, the analysis of MBD3 or of MBD3–
NuRD revealed differing results concerning binding to
promoters in ES cells (7,16,38,39). As discussed previously
(40), distribution of the NuRD complex was identiﬁed in
broad regions with a depletion at the TSS, or speciﬁcally
binding at the TSS. Here, we show that within a single cell
type, both MBD2 and MBD3 are found at the TSS tailing
into the ﬁrst exon.
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Most striking is the binding to gene bodies and exon
sequences. In general, we found MBD2 and MBD3
binding at exon sequences. However the absolute
number of cases with exon binding by MBD2 was much
higher and therefore we analysed these in detail. Primarily
internal (translated) exons are enriched for MBD2
binding. The terminal exon with varying length of the
open reading frame shows MBD2 binding enriched
within the 50-region. Previously, CpG methylation has
been seen to be enriched in the exons of active genes
(41–43). This enrichment is further speciﬁed by the fact
that non-coding exons are hypomethylated, whereas
internal and last exons are more frequently methylated
(29,44). This methylation pattern reﬂects the MBD2 dis-
tribution within the gene bodies, with declining MBD2
binding towards the 30-end of the last exon, which
usually is not translated. Furthermore, we ﬁnd a correl-
ation of MBD2 binding to internal exons and gene
activity. It has been suggested that this methylation
pattern may foreshadow the content of mature mRNA
(41). A functional connection between DNA methylation
and splicing has been recently demonstrated at the CD45
gene. In this case, methylation inhibits binding of CTCF,
which inﬂuences the splicing reaction (45). Here we are
extending this idea that MBD2 binding may affect
splicing, although formally, the reverse may be true as
well in that the transcribing polymerase/splicing complex
may determine CpG methylation and MBD2 binding.
Thus, what has been generally called the NuRD repres-
sor complex turns out to be associated with a diverse set of
functions, such as repression, activation and potentially
connecting chromatin with splicing.
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